Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (LRMR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lrmr · stock forecast · 8 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$12.00
+287.8% upside
Low
$12.00
Median: $12 · Last Close: $3.09
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.94 | ↓ 5.00% |
1-day model range: $2.91–$2.97. Peak: $2.97 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LRMR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-18 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-20 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-03 | Wedbush | Maintains | Outperform→Outperform |
| 2026-02-25 | Citigroup | Maintains | Buy→Buy |
| 2026-02-25 | Wedbush | Maintains | Outperform→Outperform |
| 2025-10-02 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-09-30 | Baird | Maintains | Outperform→Outperform |
| 2025-09-30 | Wedbush | Maintains | Outperform→Outperform |
| 2025-08-19 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2025-08-15 | JMP Securities | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Larimar Therapeutics, Inc. (LRMR) stock. Of the recent 47 rating actions, 2 were upgrades and 1 were downgrades. 8 analysts currently cover LRMR.
Analyst Recommendation Trends
LRMR analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 98.5% YoY
Revenue Next Year
$58M
↑ 2416.4% YoY
EPS This Year
$-1.66
EPS Next Year
$-1.26
↓ 24.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast LRMR EPS of $-1.66 for the current fiscal year, based on estimates from 6 analysts. The LRMR revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LRMR stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LRMR price target is $12.00 (+287.8% upside), with an analyst consensus of Buy.
The LRMR short-term stock prediction for tomorrow is $2.94 (-5.00%).
Larimar Therapeutics, Inc. trades on NASDAQ under the ticker LRMR. The LRMR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
LRMR forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month LRMR price target is $12.00, with a high forecast of $12.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +287.8% potential upside from the current price of $3.09.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.